Karsten Juhl JÃ, rgensen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1702935/publications.pdf

Version: 2024-02-01

102 papers 4,354 citations

30 h-index 63 g-index

106 all docs

106 docs citations

106 times ranked 5611 citing authors

#	Article	IF	CITATIONS
1	EMA's mishandling of an investigation into suspected serious neurological harms of HPV vaccines. BMJ Evidence-Based Medicine, 2022, 27, 7-10.	1.7	3
2	Electroconvulsive therapy for preventing relapse and recurrence in people with depression. The Cochrane Library, 2022, 2022, .	1.5	0
3	Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532110676.	1.2	14
4	Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. The Cochrane Library, 2022, 2022, CD012857.	1.5	8
5	Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings. The Cochrane Library, 2022, 2022, CD015112.	1.5	5
6	Addressing harms of screening – A review of outcomes in Cochrane reviews and suggestions for next steps. Journal of Clinical Epidemiology, 2021, 129, 68-73.	2.4	5
7	The US Food and Drug Administration's authorisation of Purdue's controlled-release methylphenidate for adult ADHD: comments on the regulatory practice. Journal of the Royal Society of Medicine, 2021, 114, 377-380.	1.1	5
8	Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks. Cephalalgia, 2021, , 033310242110299.	1.8	0
9	Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings. The Cochrane Library, 2021, 2021, .	1.5	2
10	Health screening needs independent regular re-evaluation. BMJ, The, 2021, 374, n2049.	3.0	7
11	Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: A case study of public documents. Journal of Clinical Epidemiology, 2021, , .	2.4	2
12	Adverse effects of electroconvulsive therapy. The Cochrane Library, 2021, 2021, .	1.5	0
13	Is earlier better when it comes giving caffeine to preterm infants or are we risking unnecessary treatment and serious harm?. Acta Paediatrica, International Journal of Paediatrics, 2020, 109, 440-442.	0.7	1
14	Hand cleaning with ash for reducing the spread of viral and bacterial infections: a rapid review. The Cochrane Library, 2020, 2020, CD013597.	1.5	17
15	Suspicions of possible vaccine harms must be scrutinised openly and independently to ensure confidence. Npj Vaccines, 2020, 5, 55.	2.9	1
16	Conflicts of interest in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: associations with recommendations. The Cochrane Library, 2020, 12, MR000040.	1.5	18
17	General health checks in adults for reducing morbidity and mortality from disease. The Cochrane Library, 2019, 2019, CD009009.	1.5	76
18	Do protocols for new randomised trials take previous similar trials into account? Cohort study of contemporary trial protocols. BMJ Open, 2019, 9, e026661.	0.8	8

#	Article	IF	Citations
19	Cochrane Sustainable Healthcare: evidence for action on too much medicine. The Cochrane Library, 2019, 12, ED000143.	1.5	9
20	Screening for reducing morbidity and mortality in malignant melanoma. The Cochrane Library, 2019, 2019, CD012352.	1.5	37
21	Continuing Antipsychotic Medication for Patients With Psychotic Depression in Remission. JAMA - Journal of the American Medical Association, 2019, 322, 2443.	3.8	1
22	Screening for abdominal aortic aneurysm – Authors' reply. Lancet, The, 2019, 393, 28.	6.3	1
23	Reform of the National Screening Mammography Program in France. JAMA Internal Medicine, 2018, 178, 177.	2.6	21
24	Drawing conclusions from the VIVA trial. Lancet, The, 2018, 391, 1894.	6.3	0
25	Should we screen women for abdominal aortic aneurysm?. Lancet, The, 2018, 392, 454-456.	6.3	O
26	Benefits and harms of screening men for abdominal aortic aneurysm in Sweden: a registry-based cohort study. Lancet, The, 2018, 391, 2441-2447.	6.3	57
27	Breast Cancer Screening in Denmark. Annals of Internal Medicine, 2017, 166, 313.	2.0	102
28	National clinical guidelines for non-surgical treatment of patients with recent onset neck pain or cervical radiculopathy. European Spine Journal, 2017, 26, 2242-2257.	1.0	93
29	Breast Cancer Screening in Denmark. Annals of Internal Medicine, 2017, 167, 524.	2.0	5
30	The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. Evidence-Based Medicine, 2017, 22, 143-147.	0.6	17
31	Melanoma Screening. Dermatology, 2017, 233, 410-411.	0.9	5
32	Overview of guidelines on breast screening: Why recommendations differ and what to do about it. Breast, 2017, 31, 261-269.	0.9	32
33	The first ever Cochrane event in Russia and Russian speaking countries – Cochrane Russia Launch – Evidence-based medicine: Achievements and barriers (QiQUM 2015) International Conference, Kazan, December 7-8, 2015. International Journal of Risk and Safety in Medicine, 2017, 28, 221-226.	0.3	1
34	Breast Cancer Screening: Benefit or Harm?. JAMA - Journal of the American Medical Association, 2016, 315, 1402.	3.8	9
35	"Informed choice―in a time of too much medicineâ€"no panacea for ethical difficulties. BMJ, The, 2016, 353, i2230.	3.0	17
36	The benefits of screening–and its harms. Lancet, The, 2016, 388, 563-564.	6.3	4

#	Article	IF	CITATIONS
37	Screening for reducing morbidity and mortality in malignant melanoma. The Cochrane Library, 2016, , .	1.5	2
38	Do invitations for cervical screening provide sufficient information to enable informed choice? A cross-sectional study of invitations for publicly funded cervical screening. Journal of the Royal Society of Medicine, 2016, 109, 274-281.	1.1	16
39	Cognitive behavioural therapy for ADHD in adults: systematic review and meta-analyses. ADHD Attention Deficit and Hyperactivity Disorders, 2016, 8, 3-11.	1.7	66
40	Harms of screening for abdominal aortic aneurysm: is there more to life than a OÂ-46% disease-specific mortality reduction?. Lancet, The, 2016, 387, 308-310.	6.3	30
41	Updated screening guidelines â€" much ado about small improvements. Nature Reviews Clinical Oncology, 2016, 13, 139-140.	12.5	5
42	A Systematic Review of Resistance Training Versus Endurance Training in COPD. Journal of Cardiopulmonary Rehabilitation and Prevention, 2015, 35, 163-172.	1.2	45
43	Treatment for women with postpartum iron deficiency anaemia. The Cochrane Library, 2015, 2015, CD010861.	1.5	28
44	Effectiveness of pulmonary rehabilitation in COPD with mild symptoms: a systematic review with meta-analyses. International Journal of COPD, 2015, 10, 791.	0.9	60
45	Screening with urinary dipsticks for reducing morbidity and mortality. The Cochrane Library, 2015, 2015, CD010007.	1.5	16
46	Author reply. Ophthalmology, 2015, 122, e17.	2.5	1
47	Author reply. Ophthalmology, 2015, 122, e35-e36.	2.5	O
48	Influence of mammography screening on use of mastectomies in Denmark. Acta Oncol \tilde{A}^3 gica, 2015, 54, 133-134.	0.8	3
49	A combination of resistance and endurance training increases leg muscle strength in COPD. Chronic Respiratory Disease, 2015, 12, 132-145.	1.0	48
50	Danish evidence-based clinical guideline for use of nutritional support in pulmonary rehabilitation of undernourished patients with stable COPD. Clinical Nutrition ESPEN, 2015, 10, e33-e41.	0.5	5
51	Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ, The, 2014, 348, g3510-g3510.	3.0	56
52	General health checks don't work. BMJ, The, 2014, 348, g3680-g3680.	3.0	32
53	Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care. The Cochrane Library, 2014, , CD010130.	1.5	134
54	Lead-Time Models Produce Far Too Low Estimates of Overdiagnosis With Mammographic Screening. Journal of the American College of Radiology, 2014, 11, 1098.	0.9	3

#	Article	IF	CITATIONS
55	Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. The Cochrane Library, 2014, , CD004707.	1.5	10
56	Post-cataract Prevention of Inflammation and Macular Edema by Steroid and Nonsteroidal Anti-inflammatory Eye Drops. Ophthalmology, 2014, 121, 1915-1924.	2.5	227
57	Lead-Time Models Should Not Be Used to Estimate Overdiagnosis in Cancer Screening. Journal of General Internal Medicine, 2014, 29, 1283-1286.	1.3	32
58	Authors' reply to Lauritzen and colleagues, Newton and colleagues, and Mangin. BMJ, The, 2014, 349, g4790-g4790.	3.0	1
59	The benefits and harms of breast cancer screening. Lancet, The, 2013, 381, 799.	6.3	14
60	Thirteen years of breast screening had no measurable effect on breast cancer mortality in Norway. International Journal of Cancer, 2013, 132, 1725-1726.	2.3	2
61	Screening for breast cancer with mammography. The Cochrane Library, 2013, 2013, CD001877.	1.5	814
62	Universal health checks should be abandoned. BMJ, The, 2013, 347, f5227-f5227.	3.0	15
63	Citations of scientific results and conflicts of interest: the case of mammography screening. Evidence-Based Medicine, 2013, 18, 83-89.	0.6	19
64	Mammography screening in Norway caused substantial overdiagnosis and did not reduce late-stage breast cancers. Evidence-Based Medicine, 2013, 18, e17-e17.	0.6	1
65	General Health Checks in Adults for Reducing Morbidity and Mortality From Disease. JAMA - Journal of the American Medical Association, 2013, 309, 2489.	3.8	38
66	Overdiagnosis of breast cancer in Norway: What have the authors adjusted for?. International Journal of Cancer, 2013, 133, n/a-n/a.	2.3	2
67	The Two-County Breast Screening Trial Cannot Provide a Reliable Estimate of the Effect of Breast Cancer Screening. Radiology, 2012, 262, 729-730.	3.6	2
68	General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. BMJ, The, 2012, 345, e7191-e7191.	3.0	250
69	Recent data show that mammographic screening of asymptomatic women is effective and essential. Medical Physics, 2012, 39, 4047-4050.	1.6	2
70	Is the tide turning against breast screening?. Breast Cancer Research, 2012, 14, 107.	2.2	10
71	General health checks in adults for reducing morbidity and mortality from disease. The Cochrane Library, 2012, 10, CD009009.	1.5	173
72	Unclear methods in estimate of screening effect in women ages 40 to 49 years. Cancer, 2012, 118, 1170-1170.	2.0	1

#	Article	IF	CITATIONS
73	Why mammography screening has not lived up to expectations from the randomised trials. Cancer Causes and Control, 2012, 23, 15-21.	0.8	60
74	Regular Health Checks: Cross-Sectional Survey. PLoS ONE, 2012, 7, e33694.	1.1	8
75	Elementary flaws in the FH01 study. Lancet Oncology, The, 2011, 12, 215.	5.1	1
76	Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. BMJ: British Medical Journal, 2011, 343, d4692-d4692.	2.4	45
77	Is Mammographic Screening Justifiable Considering Its Substantial Overdiagnosis Rate and Minor Effect on Mortality?. Radiology, 2011, 260, 621-627.	3.6	114
78	The Breast Screening Programme and misinforming the public. Journal of the Royal Society of Medicine, 2011, 104, 361-369.	1.1	36
79	The proposed review will not be independent without NICE. BMJ: British Medical Journal, 2011, 343, d7533-d7533.	2.4	O
80	Unbalanced reporting of benefits and harms in abstracts on rofecoxib. European Journal of Clinical Pharmacology, 2010, 66, 341-347.	0.8	4
81	Breast screening: why estimates differ by a factor of 20-25. Journal of Medical Screening, 2010, 17, 158-159.	1.1	8
82	Who evaluates public health programmes? A review of the NHS Breast Screening Programme. Journal of the Royal Society of Medicine, 2010, 103, 14-20.	1.1	17
83	Mammography reduces breast cancer mortality in women aged 39-69 years; but harms may outweigh benefits in women under 50. Evidence-Based Medicine, 2010, 15, 62-63.	0.6	5
84	Breast cancer mortality in organised mammography screening in Denmark: comparative study. BMJ: British Medical Journal, 2010, 340, c1241-c1241.	2.4	165
85	Mammography screening is not as good as we hoped. Maturitas, 2010, 65, 1-2.	1.0	4
86	Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ: British Medical Journal, 2009, 339, b2587-b2587.	2.4	407
87	Flawed Inferences About Screening Mammography's Benefit Based on Observational Data. Journal of Clinical Oncology, 2009, 27, 639-640.	0.8	25
88	Divine intervention? A Cochrane review on intercessory prayer gone beyond science and reason. Journal of Negative Results in BioMedicine, 2009, 8, 7.	1.4	10
89	A cause for celebration, and caution. BMJ: British Medical Journal, 2009, 338, b2126-b2126.	2.4	5
90	Breast screening: the facts-or maybe not. BMJ: British Medical Journal, 2009, 338, b86-b86.	2.4	128

#	Article	IF	CITATIONS
91	Biases in estimates of overdetection due to mammography screening. Lancet Oncology, The, 2008, 9, 199-201.	5.1	15
92	Are benefits and harms in mammography screening given equal attention in scientific articles? A cross-sectional study. BMC Medicine, 2007, 5, 12.	2.3	42
93	Content of invitations for publicly funded screening mammography. BMJ: British Medical Journal, 2006, 332, 538-541.	2.4	121
94	Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. BMJ: British Medical Journal, 2004, 328, 148-0.	2.4	122
95	Cancer of the Larynx: Treatment Results after Primary Radiotherapy with Salvage Surgery in a Series of 1005 Patients. Acta Oncol \tilde{A}^3 gica, 2002 , 41 , $69-76$.	0.8	66
96	Effect of Traditional Chinese Acupuncture on Severe Tinnitus: A Double-Blind, Placebo-Controlled, Clinical Investigation with Open Therapeutic Control. International Journal of Audiology, 1998, 32, 197-204.	0.7	45
97	Influence of Late Side-Effects Upon Daily Life After Radiotherapy for Laryngeal and Pharyngeal Cancer. Acta Oncol \tilde{A}^3 gica, 1994, 33, 487-491.	0.8	102
98	Lymph Node Metastases in the Neck from Unknown Primary Tumour. Acta Oncol \tilde{A}^3 gica, 1992, 31, 653-655.	0.8	16
99	Results of Uvulopalatopharyngoplasty in Snoring. Acta Oto-Laryngologica, 1992, 112, 11-14.	0.3	16
100	Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. The Cochrane Library, $0, , .$	1.5	5
101	Conflicts of interest and recommendations in clinical guidelines, opinion pieces, and narrative reviews. The Cochrane Library, 0, , .	1.5	6
102	Electroconvulsive therapy for depression. The Cochrane Library, 0, , .	1.5	1